Metsera, Inc. (NASDAQ:MTSR – Get Free Report) shares reached a new 52-week low during trading on Thursday . The stock traded as low as $24.70 and last traded at $25.14, with a volume of 233191 shares traded. The stock had previously closed at $27.21.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on the company. Evercore ISI initiated coverage on Metsera in a research note on Tuesday. They set an “outperform” rating on the stock. Bank of America started coverage on shares of Metsera in a research report on Tuesday. They set a “buy” rating and a $38.00 price target on the stock. Guggenheim began coverage on shares of Metsera in a report on Tuesday. They issued a “buy” rating and a $56.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on shares of Metsera in a report on Tuesday. They set an “overweight” rating on the stock.
Check Out Our Latest Report on MTSR
Metsera Trading Down 4.5 %
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Stories
- Five stocks we like better than Metsera
- When to Sell a Stock for Profit or Loss
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- What is the S&P/TSX Index?
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Canadian Penny Stocks: Can They Make You Rich?
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
